Balance Sheet Parenthetical [Abstract] Balance Sheet Parenthetical [Abstract] Common stock, par value Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Research and Development [Abstract] Procurement Contract and Research Agreements Procurement Contract and Research Agreements [Text Block] The entire disclosure for procurement contracts and research agreements including grants or contracts from various agencies of the U.S. government to support the reporting entity's research and development activities. Fair Value Measurements [Abstract] Fair Value Measurements [Abstract] Fair Value Disclosures Fair Value Disclosures [Text Block] Earnings Per Share [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock Option [Member] Employee Stock Option [Member] Stock Appreciation Rights (SARs) [Member] Stock Appreciation Rights (SARs) [Member] Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) [Member] Warrants [Member] Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Restricted Stock Units Restricted Stock Units Restricted Stock Units have been vested but not converted into common stock Weighted average Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Payables and Accruals [Abstract] Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities [Text Block] The entire disclosure for accrued liabilities and other current liabilities at the end of the reporting period. Bonus Accrued Bonuses, Current Professional fees Accrued Professional Fees, Current Vacation Accrued Vacation, Current Taxes Payable Taxes Payable Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Other Other Accrued Liabilities, Current Total Accrued Liabilities, Current Liabilities Subject to Compromise [Abstract] Liabilities subject to compromise Reorganization under Chapter 11 of US Bankruptcy Code Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Tax Income Tax Disclosure [Text Block] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Document Information [Table] Document Information [Table] Document Information, Document [Axis] Document Information, Document [Axis] Document [Domain] Document [Domain] Document Information [Line Items] Document Information [Line Items] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Trading Symbol Trading Symbol Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Equity [Abstract] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Extended Expiration Period [Member] Extended Expiration Period [Member] Extended Expiration Period [Member] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Affiliated Entity [Member] Affiliated Entity [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring [Member] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Change in fair value of common stock warrants Change In Fair Value Of Common Stock Warrants The aggregate adjustment to the fair market value of liability classified warrants to purchase common stock. Commitment to Invest Commitment to Invest Related party commitment to invest at the Company's discretion in exhange for common stock and warrants. Warrants to purchase percentage of acquired shares Warrants to Purchase Percentage of Shares Related party commitment to invest at the Company's discretion in exhange for warrants to purchase a percentage of the number of Company shares acquired by the related party. Warrants to purchase common stock Class of Warrant or Right, Number of Securities Called by Warrants or Rights Proceeds from issuance of warrants and options Proceeds From Issuance Of Warrants and Options 1 The cash inflow associated with both the amount received from holders exercising their stock options and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Exercise price of warrants to purchase common stock Class of Warrant or Right, Exercise Price of Warrants or Rights Service agreement term Service Agreement Term 1 Service agreement, entered into with MacAndrews & Forbes LLC ("M&F"), in years. Warrants contractrual term Warrants contractrual term The contractual life of warrants. Expense of warrants held as assets Expense of Warrants Held as Assets The expense associated with warrants held as assets. Property, Plant and Equipment [Abstract] Property, Plant and Equipment Property, Plant and Equipment Disclosure [Text Block] Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities [Table Text Block] Tabular disclosure of the components of accrued liabilities and other current liabilities. Income Statement [Abstract] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Revenues Revenues [Abstract] Research and development Research and Development Revenue Revenue earned during the period arising from services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts and any other contract related to a particular project or product. Operating expenses Operating Expenses [Abstract] Selling, general and administrative Selling, General and Administrative Expense Research and development Research and Development Expense Patent preparation fees Patent Preparation Fees The aggregate costs incurred for fees associated with the protection and expansion of patents and related intellectual property. PharmAthene liability interest PharmAthene liability interest Amount of costs on PharmAthene liability accounted as interest expense Interest on PharmAthene liability Interest on PharmAthene liability Interest on PharmAthene liability Total operating expenses Operating Expenses Operating loss Operating Income (Loss) Decrease (increase) in fair value of common stock warrants Non-cash interest expense Interest Expense Other income, net Nonoperating Income (Expense) Reorganization items, net Reorganization Items Loss before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Benefit from (provision for) income taxes Income Tax Expense (Benefit) Net and comprehensive income (loss) Net Income (Loss) Attributable to Parent Earnings (loss) per share: basic and diluted Earnings Per Share, Basic and Diluted Weighted average shares outstanding: basic and diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case Type [Domain] Litigation Case [Domain] License Agreement litigation License Agreement Litigation [Member] License Agreement Litigation [Member] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Pending litigation Pending Litigation [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Surety bond Surety Bond [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accrued liabilities Accrued Liabilities [Member] Other assets Other Assets [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Percentage of net profits from sales after net profit threshold Percentage of Net Profits from Sales After Net Profit Milestone Resulting From Award Damages The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale. Net profit threshold Net Profit Milestone The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale Equitable payment stream following first commercial sale, duration Duration of Equitable Payment Stream Following First Commercial Sale The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale. Percentage of litigation costs awarded Litigation Costs Awarded, Percentage The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expert witness expenses. Plaintiff attorneys' fee and expenses Amount Plaintiff May Recover The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expert witness expenses. Payment to Post Collateral for Surety Bond Payment to Post Collateral for Surety Bond Payment to post collateral for surety bond. Collateral Collateral Percentage of cash collateral for surety bond. Surety bond Surety bond Amount of surety bond. Litigation costs awarded, remand proceedings Litigation Costs Awarded, Remand Proceedings The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expenses it incurred in the remand proceedings. Litigation costs awarded, pretrial and trial phases Litigation Costs Awarded, Pretrial and Trial Phases The Delaware Court of Chancery awarded PharmAthene a percentage of its expert witness fees it incurred in the pretrial and trial phases. Litigation costs awarded, expert fees remand proceedings Litigation Costs Awarded, Expert Fees Remand Proceedings The Delaware Court of Chancery awarded PharmAthene a percentage of its expert witness fees it incurred in remand proceedings. Final Order And Judgment Final Order And Judgment Final order and judgment entered by the Court awarding damages to the Plaintiff. Final order and judgment including interest Final order and judgment plus interest Final Order and Judgment entered by the Court awarding expectation damages, plus pre-judgment interest, and certain permitted legal fees, costs, and expenses to Plaintiff. Final order and judgment post-judgment interest Final Order And Judgment Post-Judgment Interest Final order and judgment post-judgment interest entered by the Court awarding damages to the Plaintiff. Per Diem Interest Per Diem Interest Per Diem Interest on post judgment amount on the Final Order Judgment entered by the court awarding damages on the PharmAthene litigation Loss Contingency Accrual Loss Contingency Accrual Final Order And Judgment Pre and Post-Judgment Interest Final Order And Judgment Pre and Post-Judgment Interest Final Order and Judgment entered by the Court awarding expectation damages, plus pre and post-judgment interest, and certain permitted legal fees, costs, and expenses to Plaintiff. Liabilities subject to compromise, loss contingency legal fees Liabilities subject to compromise, loss contingency legal fees The amount of pre-petition loss contingency liability representing legal and expert fees accrued and included in liabilities subject to compromise. Loss Contingency, Accrual, Current Loss Contingency, Accrual, Current PharmAthene liability includes reimbursable attorney and expert fee PharmAthene liability includes reimbursable attorney and expert fee PharmAthene liability includes reimbursable attorney and expert fee Inventory [Abstract] Inventory [Abstract] Inventory Schedule of Inventory, Current [Table Text Block] Current income tax expense (benefit) Current Income Tax Expense (Benefit) Income (loss) from continuing operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Domestic Write-off of leasehold improvements Gain (Loss) on Disposition of Property Plant Equipment Leasehold improvements, gross Leasehold Improvements, Gross Computer equipment, gross Computer Equipment The gross amount of capitalized computer equipment costs as of the balance sheet date. Furniture and fixtures, gross Furniture and Fixtures, Gross Property, plant and equipment, gross Property, Plant and Equipment, Gross Accumulated depreciation, depletion and amortization, property, plant, and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Property, Plant and Equipment, Net Depreciation and other amortization Depreciation, Depletion and Amortization Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Financial Instruments Disclosure [Text Block] Inventory Disclosure [Abstract] Inventory, Current [Table] Inventory, Current [Table] Procurement Contract [Axis] Procurement Contract [Axis] Procurement Contract [Axis] Procurement Contract [Domain] Procurement Contract [Domain] Procurement Contract [Domain] BARDA Contract Barda Contract [Member] Barda Contract [Member] Inventory [Line Items] Inventory [Line Items] Courses delivered provisional dosage, twice daily Courses Delivered Provisional Dosage, Twice Daily Courses of tecovirimat delivered to the Strategic Stockpile at the provisional dosage of 600 mg twice daily (1,200 mg per day). Work in process Inventory, Work in Process and Raw Materials Finished goods Inventory, Finished Goods, Net of Reserves Inventory Inventory, Net Inventory write-downs Inventory Write-downs Inventory write-downs included in research and development expense on the balance sheet. Bankruptcy Claims, Amount Paid to Settle Claims Bankruptcy Claims, Amount Paid to Settle Claims Bankruptcy Claims, Number Of Claims Outstanding Bankruptcy Claims, Number Of Claims Outstanding The aggregate number of claims outstanding with the bankruptcy court. Liabilities subject to compromise, other accrued expense Liabilities subject to compromise, other accrued expense The amount of pre-petition accrued expense included in liabilities subject to compromise. Liabilities subject to compromise, accounts payable Liabilities subject to compromise, accounts payable The amount of pre-petition trade accounts payable included in liabilities subject to compromise. Amount To Be Paid On Effective Date of Plan Of Reorganization Amount To Be Paid On Effective Date of Plan Of Reorganization The amount the Company is to pay PharmAthene on the effective date of the plan of reorganization. payment to extend 120 days to satisfy pharmAthene claim payment to extend 120 days to satisfy pharmAthene claim payment to extend 120 days to satisfy pharmAthene claim Payment To Extend Days To Satisfy Claim Payment To Extend Days To Satisfy Claim Total amount of payment to PharmAthene to extend the number of days to satisfy the claim. Covenants on pharmAthene liability Covenants on pharmAthene liability Covenants on pharmAthene liability is amounts to be paid to PharmAthene in excess of $50 million in the event of default with respect to a covenant. Liabilities Subject to Compromise Liabilities Subject to Compromise Net Capital Deficiency Net Capital Deficiency Net Capital Deficiency. Net capital is equal to the net worth of the broker dealer, less certain items such as exchange memberships, carrying value of securities not readily marketable, haircuts on marketable securities in proprietary accounts, furniture and equipment and other illiquid assets as defined. Per Share Data Earnings Per Share [Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Recent Accounting Pronouncements [Abstract] Recent Accounting Pronouncements [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Text Block] New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash Restricted Cash and Investments, Current Accounts receivable Accounts Receivable, Net, Current Prepaid expense and other assets, current Prepaid Expense and Other Assets, Current Deferred tax assets Deferred Tax Assets, Net of Valuation Allowance, Current Total current assets Assets, Current Property, plant and equipment, net Deferred costs Deferred Costs, Noncurrent Goodwill Goodwill Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Accounts payable Accounts Payable, Current Accrued expenses and other current liabilities Long-term debt, current maturities Long-term Debt, Current Maturities Total current liabilities Liabilities, Current Deferred revenue Deferred Revenue, Noncurrent Deferred income tax liability Deferred Tax Liabilities, Net, Noncurrent Other liabilities Other Liabilities Liabilities subject to compromise Total liabilities Liabilities Stockholders' equity Stockholders' Equity Attributable to Parent [Abstract] Common stock ($.0001 par value, 100,000,000 shares authorized, 53,843,044 and 53,504,296 issued and outstanding at June 30, 2015, and December 31, 2014, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Procurement Contract [Table] Procurement Contract [Table] Procurement Contract [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Procurement Contract [Line Items] Procurement Contract [Line Items] Procurement Contract [Line Items] Number of courses to be delivered Number of Courses To Be Delivered 1 Number of tecovirimat, also known as ST-246, courses to be delivered to the U.S. Strategic National Stockpile Value of contract Government Contract, Value of Award 1 Value of base contract award. Contract Value of Manufacturing and Delivery Activities Contract Value of Manufacturing and Delivery Activities Contract value of manufacturing and delivery activities. Contract value of development and support activities Contract Value of Development and Support Activities Contract value of development and support activities Contract value of various options Contract Value of Various Options Contract value of various options exercisable at BARDA's discretion. Amount of option to be received from BARDA for approval for extension of 84 moth expiry Amount of option to be received from BARDA for approval for extension of 84 moth expiry Amount of option to be received from BARDA for approval for extension of 84 moth expiry Contract Value, Option, FDA Approval Contract Value, Option, FDA Approval Contract value of option exercisable, FDA approval for extension to 84-month expiry for Tecovirimat, at BARDA's discretion. Contract Value, Detail Of Option Exercisable, Development Activities Contract Value, Detail Of Option Exercisable, Development Activities Contract value of option exercisable, amount represents exercisable option that would fund development and support activities, at BARDA's discretion. Contract Value, Detail Of Option Exercisable, Production Activities Contract Value, Detail Of Option Exercisable, Production Activities Contract value of option exercisable, amount represents exercisable option that would fund production activities, at BARDA's discretion. Number of courses under modified contract Government Contract, Number of Courses Purchased Under Modified Contract Government contract, number of courses to be purchased under modified contract. Increase in payments for delivery of courses of TPOXX Increase in payments for delivery of courses of TPOXX Increase in payments for delivery of courses of TPOXX Holdback amount pending FDA approval Holdback amount pending FDA approval Holdback amount pending FDA approval Reduced holdback amount Reduced holdback amount Reduced holdback be received from BARDA Number of courses contributed at no additional cost to the government Government Contract, Number of Free Courses Number of courses of tecovirimat to be contributed to the Strategic Stockpile at no cost to the government. Proceeds from manufacture and physical delivery of courses, government contract Proceeds From Manufacture And Physical Delivery Of Courses, Government Contracts Proceeds from manufacture and physical delivery of courses, government contracts. Number of courses delivered to the government Number of courses delivered to the government Number of courses delivered to the government Invoiced milestone Invoiced milestone Invoiced milestone Number of courses of TPOXX to be delivered to the government Number of courses of TPOXX to be delivered to the government Number of courses of TPOXX to be delivered to the government Number of free courses to be delivered to BARDA Number of free courses to be delivered to BARDA Number of free courses to be delivered to BARDA Number of courses to be delivered to the government, including free courses Number of courses to be delivered to the government, including free courses Number of courses to be delivered to the government, including free courses Proceeds from advance payments under the BARDA contract Proceeds from Advance Payments, Government Contracts Proceeds from advance payments, government contracts Milestone payment Milestone payment Proceeds from milestone payment, Government contracts Proceeds From Physical Delivery Of Courses, Government Contracts Proceeds From Physical Delivery Of Courses, Government Contracts Proceeds from physical delivery of courses, government contract. Future proceeds to be received from BARDA Future proceeds to be received from BARDA Future proceeds to be received from BARDA Future proceeds to be received from the future deliveries of courses to the government Future proceeds to be received from the future deliveries of courses to the government Future proceeds to be received from the future deliveries of courses to the government Courses delivered Number of courses delivered and accepted Number of tecovirimat, also known as ST-246, courses delivered and accepted to the U.S. Strategic National Stockpile. Number of courses delivered and accepted at provisional dosage, once daily Number Of Courses Delivered And Accepted At Provisional Dosage, Once Daily Number of tecovirimat, also known as ST-246, courses delivered and accepted at the provisional dosage of 600 mg once daily to the U.S. Strategic National Stockpile. Deferred revenue Deferred Revenue, Description Research and development revenue long-term contract Research and Development Revenue Long-term Contract Revenue earned during the period arising from research and development services provided under the terms of a long-term contract. May include government contracts and any other contract related to a particular project or product. Number of active contracts Number of Active Contracts Number of active contracts. Number of active grants Number of Active Grants Number of active grants Potential future research and development funding Potential Future Aggregate Research and Development Expenses Potential future aggregate research and development funding for specific projects which includes options that may or may not be exercised at the U.S. government's discretion. Potential milestone payments Potential milestone payments Potential later stage milestone payments and royalties. Potential royalties Potential royalties Maximum percentage of potential royalties on sales of drugs that use transferred intellectual property rights. Potential percentage cash distributions Potential percentage cash distributions Potential percentage cash distributions of profit interest units. Statement of Cash Flows [Abstract] Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income (loss) Adjustments to reconcile net income (loss) to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and other amortization Increase (decrease) in fair value of warrants Increase In Fair Value Of Warrants Noncash expense, not otherwise specified in the taxonomy, charged against earnings in the period to adjust the fair market value of liability classified warrants to purchase common stock. Stock-based compensation Share-based Compensation Gain on sale of assets Gain (Loss) on Disposition of Assets Non-cash interest expense Other Noncash Expense Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Deferred costs Increase (Decrease) in Deferred Charges Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Other assets Increase (Decrease) in Other Operating Assets Deferred income taxes, net Deferred Income Tax Expense (Benefit) Accounts payable, accrued expenses and other current liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase/decrease in PharmAthene liability Increase/decrease in PharmAthene liability Increase/decrease in PharmAthene liability value is as of balance sheet date of liability incurred and payable to PharmAthene for litigation against the Company which damages awarded to PharmAthene by the court. PharmAthene liability PharmAthene liability PharmAthene liability is carrying value as of balance sheet date of liability and payable to PharmAthene for litigation against the Company for which damages awarded to PharmAthene by the court. Liabilities subject to compromise Liabilities Subject to Compromise, Period Increase (Decrease) Deferred revenue Increase (Decrease) in Deferred Revenue Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Capital expenditures Payments to Acquire Property, Plant, and Equipment Proceeds from sale of assets Proceeds from Sale of Productive Assets Restricted Cash Payments for (Proceeds from) Other Investing Activities Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net proceeds from exercise of warrants and options Proceeds From Issuance Of Warrants and Options The cash inflow associated with both the amount received from holders exercising their stock options and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Payment of common stock tendered for employee tax obligations Payments Related to Tax Withholding for Share-based Compensation Repayments of long-term debt Repayments of Long-term Debt Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Member of Board of Directors Management [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Free rent period Free Rent Period Free Rent Period in months allowed under the sublease. Monthly rental payments first five years Monthly Rental Payments First Five Years The amount of the monthly rental payments due under the sublease entered into for the first five years. Initial rent period Initial Rent Period Represents the number of years for the initial rent period of five years and related monthly payments. Monthly rental payments after five years Monthly Rental Payments After Five Years The amount of the monthly rental payments due under the sublease entered into after the first five years. Rent period after first five years Rent Period After First Five Years Represents the amount of years after the initial rent period of first five years of which monthly rental payments will increase. Legal fees Legal Fees Accounts payable to related party Accounts Payable, Related Parties Related party expense Related Party Transaction, Expenses from Transactions with Related Party Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Term loan Debt, Long-term and Short-term, Combined Amount Inventory Inventory Disclosure [Text Block] Liabilies subject to compromise [Table Text Block] Liabilies subject to compromise [Table Text Block] [Table Text Block] for Schedule of liabilities that are subject to compromise. Reorganization items [Table Text Block] Reorganization items [Table Text Block] The schedule represents a summary of reorganization items. Schedule of antidilutive securities excluded from computation of earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Property, plant and equipment Property, Plant and Equipment [Table Text Block] Reorganization [Abstract] Reorganization [Abstract] Debtor reorganization items, Legal fees Debtor Reorganization Items, Legal and Advisory Professional Fees Reorganization, Professional fees Reorganization, Professional Fees Amount of reorganization items related to professional fees related to entities in bankruptcy. Reorganization, Trustee fees Reorganization, Trustee fees Amount of reorganization items for trustee fees related to entities in bankruptcy. Debtor Reorganization Items, Other expense Debtor Reorganization Items, Other Expense (Income) Reorganization Items Reorganization payments Reorganization Payments The amount the Company paid for reorganization items.